Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.

Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.

http://www.wikidata.org/entity/Q34362680

about

Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: A MOOSE-compliant meta-analysis.Rituximab for nephrotic syndrome in children.American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab Rituximab for troublesome cases of childhood nephrotic syndrome.The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis Rituximab Treatment for Nephrotic Syndrome in Children Nephrotic syndrome in children: from bench to treatment Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood.Rituximab in children with resistant idiopathic nephrotic syndrome.IgM contributes to glomerular injury in FSGS An unusual cause of severe persistent neutropenia in a child with nephrotic syndrome.Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.Adrenocorticotropic hormone analog use for podocytopathies Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome Rituximab in idiopathic nephrotic syndrome: does it make sense?Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.Rituximab and minimal change nephrotic syndrome: a therapeutic option.Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients.Update on the role of rituximab in kidney diseases and transplant.Rituximab in immunologic glomerular diseases.Colitis associated with biological agents Childhood nephrotic syndrome--current and future therapies.Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.Indications for use and safety of rituximab in childhood renal diseases.Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO.Rituximab therapy in nephrotic syndrome: implications for patients' management.Is rituximab effective in childhood nephrotic syndrome? Yes and no.Steroid-resistant nephrotic syndrome: impact of genetic testing.B cell depletion: rituximab in glomerular disease and transplantation Second-line immunosuppressive treatment of childhood nephrotic syndrome: a single-center experience.Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.The glomerular permeability factors in idiopathic nephrotic syndrome.Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome.High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.Podocyte-actin dynamics in health and disease.

P2860

Q30240107-E3275397-B81E-40F8-A0B9-63A653CFB8F4 Q33555088-AA4A9DF5-B66D-4B5D-8523-1260168D46F9 Q33571864-D292F448-EA14-4938-8C36-17DC02D496FB Q34130591-F2D4C5E1-7A7B-4872-AE31-B4EE3658E889 Q34683518-3E2B9C5D-9C71-45B1-93AB-8BC5F906CC82 Q35040896-65E7A483-F033-4268-B589-AF4C1B2FAFB1 Q35113681-659BA512-B465-487D-90CA-D3CB7D2FE97E Q35185376-4FFF880B-83A4-4817-8570-D4FB2560B36B Q35278415-17FF2CFD-D787-4F34-A066-5A74980CA8C2 Q35674857-F273C23E-8AD1-4167-8AF3-4E580600BD99 Q35982341-8FCA0D7A-13A7-47BD-BAF3-1E4EEA4DC57A Q36638347-E34E8A03-2E41-487A-B53C-BB1BF524C102 Q36704943-0A0C09CE-108B-4808-B9DB-AE64BDDCC682 Q36770915-50BCDF0C-5089-43AD-9142-908B1A4ACEFB Q37070458-E33C8756-FA4F-4E45-93F6-7FD39A831B53 Q37108328-EB48D373-1D2B-44F0-83ED-DA2F154ECA76 Q37275486-E93832AC-3B41-4208-B21B-FE59BB42DE56 Q37375752-276830A8-2686-4843-9401-60EA0B23459C Q37728395-269841D4-F0AB-42C1-91CC-106C89D5A0B2 Q37879578-41C218B2-39EE-42FA-BEFB-A2CF4BFC6FA0 Q37928188-58AE2099-80C9-42DD-BC8E-1BCE1844352B Q37970443-18F466F3-119A-4528-A5BB-CF20E7E7D770 Q37989298-9352F989-44C9-49D6-8DF9-47B8F01B3AC6 Q38007938-75AB811C-2434-46A0-9335-99CC8581CC1A Q38017937-8A417D26-9263-4841-9C98-97EE5DA574C3 Q38026511-61F86EC4-252D-441E-938F-3FDB6C567CF6 Q38044851-937D351E-DA69-4B13-ACDE-7D8A3F4FDFBC Q38050959-C7984A04-837D-4B61-B65E-5CC8227FD9C7 Q38075787-1DD48202-E8D4-43FD-A76A-598A703EF79F Q38118894-172F1D09-FF17-4726-9552-45F01D3A0EE2 Q38177662-94BB5921-5919-44FE-8AF3-CDC09591BE5D Q38189360-6D6CF760-0369-472D-B117-8C51BFC60827 Q38191615-B26A75C4-A7C6-48BB-ACA3-8BEE35E5D3EF Q38206050-8A094819-FAB1-4C94-8352-84323C9ABC77 Q38449629-39D00564-B639-48DD-B703-425E5AF820C0 Q38597096-24145DEA-C68B-450D-8373-4FDD958FAA3A Q38658597-C1499540-7FC2-4E02-956C-FCBEB3E5027C Q38679589-5B4022F6-7BA4-4945-A090-4E9F26934153 Q38895019-420E3366-1ABE-4666-B7C5-AA78B72A54E9 Q38940494-196E8CF3-9516-406D-BCB4-FE86A0809956

P2860

Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.

http://www.wikidata.org/entity/Q34362680

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efficacy and safety of treatme ...... syndrome: multicentric report.

@ast

Efficacy and safety of treatme ...... syndrome: multicentric report.

@en

Efficacy and safety of treatme ...... syndrome: multicentric report.

@nl

type

label

Efficacy and safety of treatme ...... syndrome: multicentric report.

@ast

Efficacy and safety of treatme ...... syndrome: multicentric report.

@en

Efficacy and safety of treatme ...... syndrome: multicentric report.

@nl

prefLabel

Efficacy and safety of treatme ...... syndrome: multicentric report.

@ast

Efficacy and safety of treatme ...... syndrome: multicentric report.

@en

Efficacy and safety of treatme ...... syndrome: multicentric report.

@nl

P1433

Q34362680-74BE368F-FF05-4C2E-9614-E5C90A2A3A4D

P1476

Q34362680-AA4609DE-4A95-4C30-A82A-D04DFA27C45B

P2093

Q34362680-44AFF716-012A-41BB-B06E-7E8F7D6878BF

Q34362680-56E225C2-2FE9-4434-AD22-C357C97029EC

Q34362680-5CD5CBE9-2779-48EC-BBC7-2A9C33C1EF5C

Q34362680-66A0D025-C486-4019-9E1C-DAAE1EF05F0A

Q34362680-85973009-2CF9-416E-8C29-438C34082FB6

Q34362680-A3A2E71C-4753-4D6F-BA17-96E7CFC87AD5

Q34362680-B42635AC-2EC8-4909-8555-60128C9E5655

Q34362680-E9F00FCC-8649-4898-9D89-A3BF27AE2ECD

Q34362680-F8C4E480-2AAF-4220-809A-08A21DC43D01

P2860

Q34362680-088F1E90-A3A9-4E70-8906-95827556D72A

Q34362680-1200DE67-9011-407B-9637-33E77C1755A9

Q34362680-2713C9F2-BFD9-4745-9E2D-65B3EF32B4B9

Q34362680-3F3F767B-4C8D-420E-9645-06D359539135

Q34362680-43D689C7-9228-4D3C-B062-B562C0B383C5

Q34362680-4790849A-D01B-43E6-A595-7DD988331346

Q34362680-4A662FB5-B5F2-44CA-A5E2-A18F2E22AF6B

Q34362680-7C4C51D1-CB92-466F-8BE6-D1510287D2CC

Q34362680-8678A077-A95D-408E-9FF5-F9F8B104EC1B

Q34362680-870A6D97-2A59-42E3-BED7-6C779CB357FD

P304

Q34362680-719CC6C8-FDD8-4142-804F-C8460CF7A9AC

P31

Q34362680-18F18109-0F62-4B91-A206-220E237AD81B

P356

Q34362680-94D66B36-2718-4CBE-BB9F-5EE917AB2C30

P433

Q34362680-C7AA6255-6925-43B6-870D-A29C3E713D23

P478

Q34362680-824E8D93-10DE-4CE4-9F89-94B7B9CFDBD1

P577

Q34362680-0F841701-BB8E-4BB0-962F-452BBA64630E

P698

Q34362680-11A64ED5-494F-43A6-A4FE-51CA8A250220

P932

Q34362680-76581FE5-1BEE-4C32-BE64-9AD73C85E3F9

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Efficacy and safety of treatme ...... syndrome: multicentric report.

@en

P2093

Aditi Sinha

http://www.w3.org/2001/XMLSchema#string

Amit K Dinda

http://www.w3.org/2001/XMLSchema#string

Arvind Bagga

http://www.w3.org/2001/XMLSchema#string

Asha Moudgil

http://www.w3.org/2001/XMLSchema#string

Ashima Gulati

http://www.w3.org/2001/XMLSchema#string

Pankaj Hari

http://www.w3.org/2001/XMLSchema#string

Rajendra N Srivastava

http://www.w3.org/2001/XMLSchema#string

Sonika Sharma

http://www.w3.org/2001/XMLSchema#string

Stanley C Jordan

http://www.w3.org/2001/XMLSchema#string

P2860

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura.

Evaluation of the obese patient. Practical considerations.

Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children.

Therapeutic options for resistant lupus nephritis.

Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts.

Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.

Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis.

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.

Rituximab treatment in rheumatoid arthritis: how does it work?

P304

2207-2212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.03470410

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20798255

http://www.w3.org/2001/XMLSchema#string

P932

2994081

http://www.w3.org/2001/XMLSchema#string